Adverse Events Reporting

Reporting suspected adverse reactions is important. Healthcare professionals are asked to report any suspected adverse reaction to the MHRA. Reporting forms and information can be found at:

www.mhra.gov.uk/yellowcard

Any suspected adverse reactions should also be reported to Gilead Sciences Ltd via email to safety_FC@gilead.com or by telephone 01223897500.

Please note that Gilead Medical Information will forward the reports to our Drug Safety and Public Health Department, which in certain circumstances may contact you for more information about a report.

Gilead Sciences Ltd consistently collates and reviews product safety information received from clinical trials and post-marketing activities. The information received is evaluated on an on-going basis ensuring the continuous surveillance of Gilead Sciences Ltd products.

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.